October 2026 brings two practical shifts for acne care: prescription-strength adapalene-benzoyl peroxide is moving over the counter, and a first-in-class oral sebum drug is entering Phase 3. Acne vulgaris, the common condition that clogs pores and causes pimples and deep lumps, now has wider store access plus a new research path. The changes build on recent dermatology guidance and federal safety testing. Readers can act now on store availability and product checks, while the newest pill remains investigational.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official notice from FDA — Use this primary source to verify the official announcement.
- Read the official guidance from Globenewswire — Use this primary source to verify the official guidance.
Table of Contents
- Can you buy prescription-strength Epiduo without a prescription?
- What is the new oral drug in Phase 3?
- Where do triple-combination topicals fit now?
- Should you still use benzoyl peroxide?
- What do dermatologists recommend first?
Can you buy prescription-strength Epiduo without a prescription?
Galderma received FDA approval on May 22, 2026 to switch Differin Epiduo Gel, adapalene 0.1% plus benzoyl peroxide 2.5%, from prescription to over the counter for ages 12 and older. Galderma said in its BusinessWire approval announcement that U.S. retail launch was planned for summer 2026.
The switch expands access to a fixed-dose combination, meaning two actives in one product. It matters most for teens and adults 12 and older who already use separate retinoid and benzoyl peroxide products. Check the box for age use, adapalene 0.1% and benzoyl peroxide 2.5%, and OTC labeling before purchase. Ask a pharmacist or dermatologist how it fits your current routine.
What is the new oral drug in Phase 3?
Sagimet Biosciences received FDA IND clearance and a Study May Proceed letter on Aug. 13, 2026 for oral denifanstat in adolescents and adults with moderate-to-severe acne. Sagimet described in its GlobeNewswire Phase 3 notice a fatty-acid-synthase inhibitor that targets sebum production.
Sebum is the skin oil that mixes with dead cells and clogs pores. This oral pathway is the first novel sebum-targeted mechanism for acne in decades. The drug is not available by prescription yet. Trial participants will be adolescents and adults with moderate-to-severe disease, so mild acne is not the focus.
Where do triple-combination topicals fit now?
Bausch Health and Ortho Dermatologics received FDA approval on Oct. 20, 2023 for Cabtreo, clindamycin phosphate 1.2% plus adapalene 0.15% plus benzoyl peroxide 3.1%. It was the first fixed-dose triple-combination topical for acne vulgaris in patients 12 and older.
It sets the current baseline for multi-mechanism care in one tube. The formula pairs an antibiotic, a retinoid, and benzoyl peroxide together. That structure supports fewer layers and more consistent use. A dermatologist may consider it when separate singles cause confusion or missed doses.
Should you still use benzoyl peroxide?
Federal testing announced March 11, 2025 found more than 90% of 95 tested benzoyl-peroxide products had undetectable or extremely low benzene. Six lots from La Roche-Posay Effaclar Duo, Proactiv, Walgreens, SLMD, and Zapzyt were voluntarily recalled at retail, according to the FDA benzene testing statement. The same FDA statement said added cancer risk remains very low even with daily use of recalled products for decades.
Patients need not panic but should check lots and storage. Keep products in cool places and discard discolored or expired tubes. Match the lot number on your tube to the recall list before continued use.
What do dermatologists recommend first?
The American Academy of Dermatology 2024 guidelines, published in the Journal of the American Academy of Dermatology, strongly recommend topical benzoyl peroxide, retinoids with or without antibiotics, and fixed-dose combinations. They also strongly recommend oral doxycycline and oral isotretinoin for severe, scarring, distressing, or treatment-resistant acne.
The same guidelines give conditional support to topical clascoterone, salicylic and azelaic acids, oral minocycline and sarecycline, hormonal options, and spironolactone. Cost and equitable access shaped several conditional ratings. Bring your current topicals list to the visit and ask whether a combined product could replace two separate steps.
- Use combined mechanisms when one active is not enough
- Limit long courses of systemic antibiotics when possible
- Reserve isotretinoin for severe or scarring cases under supervision